Barbiturates are a class of sedative drugs that slow down the central nervous system. First synthesized in 1863 and introduced as a medication in 1903, they were once among the most widely prescribed drugs in the world. Today they’ve been largely replaced by safer alternatives, but they still play a role in treating seizures, inducing anesthesia, and managing a handful of other serious medical conditions.
How Barbiturates Work in the Brain
Your brain has a natural braking system built around a chemical messenger called GABA. When GABA attaches to its receptor on a nerve cell, it opens a channel that lets chloride ions flow in, which quiets the cell and makes it less likely to fire. Barbiturates bind to a separate site on that same receptor and amplify this effect. Specifically, they increase the amount of time those chloride channels stay open, shifting the channels toward their longest open state (about 9 milliseconds) and away from their shorter open states. The result is a significant increase in chloride flow, which calms neural activity across the brain.
At low doses, this produces relaxation and drowsiness. At higher doses, it can cause full sedation, loss of consciousness, or a medically induced coma. At very high doses, barbiturates suppress the brain’s respiratory center, the area responsible for the automatic drive to breathe. This is the primary way barbiturate overdoses become fatal.
Types of Barbiturates
Barbiturates are grouped by how long their effects last:
- Ultra-short-acting: Effects last minutes. Methohexital and thiopental fall into this category and are used mainly to induce anesthesia or for brief procedural sedation.
- Short-acting: Effects last a few hours. Secobarbital is the most recognized example and was historically prescribed for insomnia.
- Intermediate-acting: Effects last several hours. Amobarbital belongs here and has been used for anxiety and sleep.
- Long-acting: Effects can last a full day or longer. Phenobarbital is the most commonly prescribed barbiturate today, used primarily to control seizures.
Current Medical Uses
Barbiturates were once prescribed for everything from anxiety to insomnia, but most of those uses have shifted to benzodiazepines and newer medications. The medical situations where barbiturates still matter tend to be serious or specialized.
Phenobarbital remains a go-to medication for seizure disorders, particularly in newborns and children. In status epilepticus, a dangerous condition where seizures don’t stop on their own, phenobarbital has proven more effective than some other options at stopping seizure activity within 60 minutes. Primidone is another barbiturate still prescribed for seizure management.
In neurosurgery and traumatic brain injury, barbiturates are sometimes used to induce a coma that lowers the brain’s oxygen demand and reduces dangerous swelling. Pentobarbital is the most common choice for this purpose. Methohexital, an ultra-short-acting barbiturate, is preferred for electroconvulsive therapy and brief procedures like setting broken bones or performing cardioversions, because its effects wear off quickly.
Why They Were Replaced
The core problem with barbiturates is their narrow therapeutic index, meaning the gap between an effective dose and a dangerous one is small. A slight overdose can cause coma or death. Benzodiazepines, which became popular in the 1960s and 1970s, work on the same GABA receptor system but are far harder to fatally overdose on when taken alone. This wider safety margin is the main reason benzodiazepines took over for conditions like anxiety and insomnia.
Barbiturates also carry a high risk of physical dependence. The body adapts to their presence quickly, requiring higher doses to achieve the same effect. And unlike many other drugs, stopping barbiturates abruptly after regular use can be life-threatening.
Dependence and Withdrawal
Physical dependence on barbiturates can develop within weeks of regular use. Withdrawal is one of the most medically dangerous of any drug class, comparable to alcohol withdrawal. For short- and intermediate-acting barbiturates (those with a half-life of 8 to 40 hours), withdrawal symptoms typically begin within one to three days after the last dose. These start with anxiety, tremors, insomnia, and nausea.
The more dangerous phase follows. Seizures and delirium can develop three to eight days into withdrawal, even in people with no prior history of epilepsy. These are typically full-body generalized convulsions. Because of this risk, barbiturate dependence is never treated by simply stopping the drug. A gradual, medically supervised taper is necessary.
Overdose Risks
Barbiturate overdose depresses the brainstem’s respiratory center, slowing and eventually stopping breathing. Death most commonly results from respiratory failure or from pneumonia that develops after prolonged respiratory depression. Combining barbiturates with alcohol, opioids, or other sedatives dramatically increases this risk because all of these substances suppress breathing through overlapping mechanisms.
There is no widely available antidote for barbiturate overdose the way naloxone reverses opioid overdoses. Treatment is supportive, focused on maintaining breathing and circulation until the drug clears the body.
Drug Interactions
Barbiturates are powerful activators of liver enzymes, particularly a family of enzymes responsible for breaking down many common medications. When barbiturates ramp up these enzymes, other drugs get processed and eliminated faster than expected, reducing their effectiveness. This is a concern with blood thinners, birth control pills, corticosteroids, certain heart medications, and other anti-seizure drugs. If you’re taking phenobarbital or another barbiturate, the dosing of your other medications may need adjustment.
Legal Status
All barbiturates are controlled substances in the United States. Their exact scheduling under the Controlled Substances Act varies by type. Amobarbital and secobarbital are classified as Schedule II, the same category as oxycodone and fentanyl, reflecting their high potential for abuse. Phenobarbital is Schedule IV, recognizing its lower abuse potential and continued medical value. Some formulations fall into Schedule III. Barbiturates require a prescription and are tracked through state prescription monitoring programs.
A Brief History
The story starts in 1863, when German chemist Adolf Baeyer synthesized barbituric acid, the parent compound of all barbiturates. The name reportedly comes from Saint Barbara, the patron saint of artillerymen, because Baeyer made his discovery on December 4, her feast day, and celebrated that evening at a tavern popular with artillery officers.
The first barbiturate used as a medication, barbital, appeared in 1903. It was marketed under the trade name Veronal (named after the Italian city of Verona) and sold as a sleep aid, even available in cocoa-flavored tablets. Over the following decades, more than 2,500 barbiturate compounds were synthesized, and about 50 reached the market. They dominated the treatment of anxiety, insomnia, and epilepsy for much of the 20th century before benzodiazepines largely displaced them starting in the 1970s.